Abstract
Bayer is paying $425 million for KaNDy Therapeutics, a UK firm developing a small-molecule treatment to reduce hot flashes from menopause. Bayer touts the investment as its latest move in women’s health, after signing a license for Daré Bioscience’s experimental monthly contraceptive and forming a gynecological disease research pact with Dewpoint Therapeutics. KaNDy’s lead compound, NT-814, inhibits neurokinin-1 and neurokinin-3 receptors, which are involved in regulating body heat. KaNDy could earn up to $450 million in milestone payments from Bayer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
